Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model
- PMID: 2805274
- DOI: 10.1161/01.cir.80.5.1388
Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model
Abstract
Myocardial salvage after reperfusion may be limited by deleterious vascular changes in the previously ischemic microcirculatory bed. This could result in a progressive decrease in blood flow in the capillary bed to potentially viable myocytes (no-reflow phenomenon). The effect of intracoronary adenosine on these changes was assessed in 15 closed-chest dogs subjected to 2 hours of proximal left anterior descending artery (LAD) occlusion followed by 3 hours of reperfusion. Animals randomly received adenosine (n = 8) 3.75 mg/min into the proximal LAD or an equivalent volume of saline (control) (n = 7) for 1 hour after reperfusion. Endothelial-dependent and independent coronary vasodilator reserve was determined using a chronically implanted volume-flowmeter on the mid-LAD at baseline and 1 and 3 hours after reperfusion with acetylcholine and papaverine infusions, respectively, into the proximal vessel. Regional myocardial blood flow was measured serially with radioactive microspheres and regional contractile function with contrast ventriculography. Both agonists produced a significant increase in LAD flow before occlusion. Endothelial-dependent and independent vasodilatory reserve was significantly reduced (p less than 0.05) at 1 and 3 hours after reperfusion in control animals compared with adenosine treatment. A progressive decrease in mid-LAD flow and increase in coronary vascular resistance after reperfusion was observed in control animals (p less than 0.05). The treated group manifested improved regional myocardial blood flow in endocardial regions from the central (0.73 +/- 0.15 versus 0.24 +/- 0.11 ml/g/min; p less than 0.02) and lateral ischemic zones (0.80 +/- 0.15 versus 0.34 +/- 0.12 ml/g/min; p less than 0.05) 3 hours after reperfusion. A significant reduction (p less than 0.05) in endocardial and midmyocardial flow compared with baseline was seen in control animals at 3 hours. Intravascular and interstitial neutrophil infiltration was reduced in adenosine animals and this was associated with relative ultrastructural preservation of endothelial cells. Regional ventricular function in the ischemic zone was improved in the adenosine group 3 hours after reperfusion (13.4 +/- 3.9% versus -5.3 +/- 1.6%; p less than 0.001). This study demonstrates that selective administration of adenosine after reperfusion significantly attenuates functional and structural abnormalities in the microvasculature after prolonged (2 hours) regional ischemia in the canine model. Prevention of microvascular injury and the non-reflow phenomenon by adenosine may preserve reversibly injured myocytes following restoration of blood flow to previously ischemic myocardium.
Similar articles
-
Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow.Am Heart J. 1990 Oct;120(4):808-18. doi: 10.1016/0002-8703(90)90196-5. Am Heart J. 1990. PMID: 2220534
-
Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period.Circulation. 1991 Jan;83(1):237-47. doi: 10.1161/01.cir.83.1.237. Circulation. 1991. PMID: 1984882
-
Does preconditioning protect the coronary vasculature from subsequent ischemia/reperfusion injury?Circulation. 1993 Aug;88(2):659-72. doi: 10.1161/01.cir.88.2.659. Circulation. 1993. PMID: 8339428
-
Mechanisms and therapy of myocardial reperfusion injury.Circulation. 1990 Mar;81(3 Suppl):IV69-78. Circulation. 1990. PMID: 2407376 Review.
-
Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent.Am J Cardiovasc Drugs. 2004;4(3):159-67. doi: 10.2165/00129784-200404030-00003. Am J Cardiovasc Drugs. 2004. PMID: 15134468 Review.
Cited by
-
Cardiac purinergic signalling in health and disease.Purinergic Signal. 2015 Mar;11(1):1-46. doi: 10.1007/s11302-014-9436-1. Epub 2014 Dec 20. Purinergic Signal. 2015. PMID: 25527177 Free PMC article. Review.
-
Adenosine and cardioprotection during reperfusion--an overview.Mol Cell Biochem. 2003 Sep;251(1-2):153-9. Mol Cell Biochem. 2003. PMID: 14575317 Review.
-
Novelties in pharmacological management of cardiopulmonary resuscitation.Curr Opin Crit Care. 2013 Oct;19(5):417-23. doi: 10.1097/MCC.0b013e328364d7b1. Curr Opin Crit Care. 2013. PMID: 23995130 Free PMC article. Review.
-
Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial.Eur Heart J. 2016 Jun 21;37(24):1910-9. doi: 10.1093/eurheartj/ehw136. Epub 2016 May 4. Eur Heart J. 2016. PMID: 27147610 Free PMC article. Clinical Trial.
-
Coronary Microvascular Function and Beyond: The Crosstalk between Hormones, Cytokines, and Neurotransmitters.Int J Endocrinol. 2015;2015:312848. doi: 10.1155/2015/312848. Epub 2015 Jun 1. Int J Endocrinol. 2015. PMID: 26124827 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources